Physician profile
Robert Leslie Klein
NPI 1114298452
$260.70
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.00 · 2020: $39.79 · 2021: $62.43 · 2022: $42.04 · 2023: $52.68 · 2024: $17.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $70.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $70.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $91.84 | 2019-2021 | |
| Agile Therapeutics, INC. | $77.71 | 2021-2024 | Twirla |
| Organon LLC | $42.04 | 2022 | |
| Abbvie INC. | $18.62 | 2019 | |
| Lupin INC. | $15.65 | 2021 | |
| Lilly USA, LLC | $14.84 | 2023 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.